Fig. 2From: A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthmaOxygen saturation measured by pulse oximetry, placebo vs S1226. The absolute change between pre-dose and post-dose %SpO2 levels was significantly different (P = 0.028) for the S1226 group compared with the placebo group over time. %SpO2 significantly decreased 5 min post-treatment following the allergen challenge for the placebo *P < 0.001 but not for S1226 (P = 0.267). Error bars show standard errors. PA pre-allergenBack to article page